```
=> s CNTF or hCNTF or AX-15
          2838 CNTF OR HCNTF OR AX-15
Ll
=> s l1 (40a) obes### or diabetes
        331027 L1 (40A) OBES### OR DIABETES
=> s l1 (40a) (obes### or diabetes)
            35 L1 (40A) (OBES### OR DIABETES)
L3
=> duplicate remove
ENTER L# LIST OR (END):13
DUPLICATE PREFERENCE IS 'MEDLINE, BIOSIS, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L3
             25 DUPLICATE REMOVE L3 (10 DUPLICATES REMOVED)
=> d 1-25
     ANSWER 1 OF 25 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
ΑN
     2002:347999 BIOSIS
DN
     PREV200200347999
TI
     Remedies for diabetes.
     Kishino, Michiko (1); Nakayama, Chikao; Taiji, Mutsuo; Ichihara, Junji;
ΑU
     Noguchi, Hiroshi
CS
     (1) Suita Japan
     ASSIGNEE: Sumitomo Pharmaceuticals Co., Limited, Osaka-fu, Japan
PT
     US 6391312 May 21, 2002
     Official Gazette of the United States Patent and Trademark Office Patents,
SO
     (May 21, 2002) Vol. 1258, No. 3, pp. No Pagination.
     http://www.uspto.gov/web/menu/patdata.html. e-file.
     ISSN: 0098-1133.
DT
     Patent
LA
     English
L4
     ANSWER 2 OF 25 USPATFULL
AN
       2002:112887 USPATFULL
TT
       Antioxidants and intracellular glutathione raising agents for
       therapeutic treatments
IN
       Noble, Mark David, Sandy, UT, UNITED STATES
       Mayer - Proschel, Margot, Sandy, UT, UNITED STATES
PT
       US 2002058628
                          A1
                               20020516
ΑĮ
       US 2001-851717
                          A1
                               20010509 (9)
RLI
       Continuation of Ser. No. US 1998-94100, filed on 9 Jun 1998, ABANDONED
DT
       Utility
FS
       APPLICATION
LN.CNT 1403
INCL
       INCLM: 514/018.000
       INCLS: 514/178.000; 514/458.000; 514/475.000
NCL
       NCLM: 514/018.000
       NCLS: 514/178.000; 514/458.000; 514/475.000
TC
       [7]
       ICM: A61K038-06
       ICS: A61K031-57; A61K031-355; A61K031-375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 3 OF 25 USPATFULL
AN
       2002:22114 USPATFULL
TI
       Assay systems for leptin-enhancing agents
TN
       Carpenter, Laura R., Tuckahoe, NY, UNITED STATES
       Stahl, Neil, Carmel, NY, UNITED STATES
       Yancopoulos, George D., Yorktown Heights, NY, UNITED STATES
PΤ
       US 2002012949
                          A1
                               20020131
AΤ
      US 2001-894039
                          A1
                               20010628 (9)
RLI
      Division of Ser. No. US 1998-93814, filed on 9 Jun 1998, GRANTED, Pat.
      No. US 6270981
PRAI
      US 1997-49108P
                           19970609 (60)
DT
      Utility
```

```
FS
      'APPLICATION
LN.CNT 993
INCL
       INCLM: 435/007.100
       INCLS: 514/002.000; 514/012.000
NCL
       NCLM: 435/007.100
       NCLS: 514/002.000; 514/012.000
TC
        [7]
       ICM: G01N033-567
       ICS: G01N033-53; A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 4 OF 25 USPATFULL
T.4
ΆN
       2002:1082 USPATFULL
ТΤ
       Incorporation of phosphorylation sites
IN
       Inglese, James, Dayton, NJ, United States
       Glickman, Joseph Fraser, Garwood, NJ, United States
PA
       Pharmacopeia, Inc., Cranbury, NJ, United States (U.S. corporation)
DT
                                20020101
       US 6335176
                          B1
       US 1998-174216
                                19981016 (9)
AΤ
DТ
       Utility
ES
       GRANTED
LN.CNT 1088
       INCLM: 435/007.720
INCL
       INCLS: 435/068.100; 530/329.000; 530/345.000
NCL.
       NCLM: 435/007.720
       NCLS: 435/068.100; 530/329.000; 530/345.000
       [7]
TC
       ICM: C07K001-113
       ICS: C07K001-13; C07K007-06; C12P021-00; G01N033-58
EXF
       530/300; 530/326; 530/327; 530/328; 530/329; 530/345; 435/7.72; 435/15;
       435/68.1; 435/132; 435/194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 5 OF 25 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
T.4
     2
AN
     2001:566553 BIOSIS
DN
     PREV200100566553
TT
     Modulators of leaderless protein export and methods for identifying and
     using the same.
ΑU
     Florkiewicz, Robert Z.; Baird, Andrew; Warnock, Dale E. (1)
CS
     (1) San Diego, CA USA
     ASSIGNEE: Ciblex Corporation
PΙ
     US 6306613 October 23, 2001
SO
     Official Gazette of the United States Patent and Trademark Office Patents,
     (Oct. 23, 2001) Vol. 1251, No. 4, pp. No Pagination. e-file.
     ISSN: 0098-1133.
DΤ
     Patent
T.A
     English
L4
     ANSWER 6 OF 25 USPATFULL
AN
       2001:202396 USPATFULL
TI
       Method for screening comprising cells expressing the CNTF receptor
TN
       Davis, Samuel, New York, NY, United States
       Squinto, Stephen P., Irvington, NY, United States
       Furth, Mark E., Pelham, NY, United States
       Yancopoulos, George D., Briarcliff Manor, NY, United States
PA
       Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.
       corporation)
PΤ
       US 6316206
                          B1
                               20011113
AΙ
       US 1998-211590
                               19981214 (9)
RLT
       Continuation of Ser. No. US 1995-445073, filed on 19 May 1995, now
       patented, Pat. No. US 5849897 Division of Ser. No. US 1991-676647, filed
       on 28 Mar 1991, now patented, Pat. No. US 5426177 Continuation-in-part
       of Ser. No. US 1990-532285, filed on 1 Jun 1990, now abandoned
DT
      Utility
FS
      GRANTED
LN.CNT 1858
INCL
       INCLM: 435/007.200
       INCLS: 435/007.100; 435/007.210; 435/069.100; 435/325.000; 536/023.500
```

```
NČL
      NCLM: 435/007.200
                                 .210; 435/069.100; 435/325.000;
       NCLS: 435/007.100; 435/0
IC
       [7]
       ICM: G01N033-53
       435/7.21; 435/7.2; 435/325; 435/69.1; 536/23.5; 536/24.31
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
T.4
     ANSWER 7 OF 25 USPATFULL
       2001:125754 USPATFULL
AN
       Methods of screening competitors of OB-R binding to SHP-2-SH2 peptides
ΤI
       Carpenter, Laura R., Tuckahoe, NY, United States
IN
       Stahl, Neil, Carmel, NY, United States
       Yancopoulos, George D., Yorktown Heights, NY, United States
       Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.
PA
       corporation)
                               20010807
       US 6270981
                          В1
PΤ
                               19980609 (9)
       US 1998-93814
ΑТ
DТ
       Utility
FS
       GRANTED
LN.CNT 968
       INCLM: 435/007.210
INCL
       INCLS: 435/007.100; 435/007.200
       NCLM: 435/007.210
NCL
       NCLS: 435/007.100; 435/007.200
TC
       [7]
       ICM: G01N033-567
       ICS: G01N033-53
EXF
       435/7.1; 435/7.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
                                                         DUPLICATE 3
     ANSWER 8 OF 25
                        MEDLINE
T.4
ΑN
     2001248451
                    MEDLINE
              PubMed ID: 11259650
DN
     21192683
     Ciliary neurotrophic factor activates leptin-like pathways and reduces
TΤ
     body fat, without cachexia or rebound weight gain, even in
     leptin-resistant obesity.
     Comment in: Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4279-81
CM
     Lambert P D; Anderson K D; Sleeman M W; Wong V; Tan J; Hijarunguru A;
ΑU
     Corcoran T L; Murray J D; Thabet K E; Yancopoulos G D; Wiegand S J
     Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY
CS
     10591, USA.. philip.lambert@regpha.com
     PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
SO
     AMERICA, (2001 Apr 10) 98 (8) 4652-7.
     Journal code: 7505876. ISSN: 0027-8424.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
FŞ
     Priority Journals
EΜ
     200105
     Entered STN: 20010517
ED
     Last Updated on STN: 20010517
     Entered Medline: 20010510
     ANSWER 9 OF 25 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
L4
     2001:540835 BIOSIS
AN
DN
     PREV200100540835
     Activation of the medial arcuate nucleus is key for suppression of
TТ
     appetite by CNTF or leptin.
ΑU
     Anderson, K. D. (1); Lambert, P. D. (1); Murray, J. D. (1); Thabet, K. E.
     (1); Tan, J. (1); Yancopoulos, G. D. (1); Wiegand, S. J. (1)
     (1) Regeneron Pharmaceuticals, Inc, Tarrytown, NY USA
CS
     Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 1674.
SO
     print.
     Meeting Info.: 31st Annual Meeting of the Society for Neuroscience San
     Diego, California, USA November 10-15, 2001
     ISSN: 0190-5295.
DΤ
     Conference
LA
     English
SL
     English
```

```
RIGHT 2002 BIOLOGICAL ABSTRACTS
                      BIOSIS
     ANSWER 10 OF 25
AN
     2001:150400 BIOSIS
DN
     PREV200100150400
     Inhibitors of leaderless protein export.
ΤТ
AU
     Florkiewicz, Robert Z.; Baird, Andrew
     ASSIGNEE: Ciblex Corporation
PΙ
     US 6083706 July 04, 2000
     Official Gazette of the United States Patent and Trademark Office Patents,
     (July 4, 2000) Vol. 1236, No. 1, pp. No Pagination. e-file.
     ISSN: 0098-1133.
DT
     Patent
LA
     English
     ANSWER 11 OF 25 USPATFULL
L4
       2000:21215 USPATFULL
AN
       Device and method for encapsulated gene therapy
ТT
       Hammang, Joseph P., Barrington, RI, United States
IN
       Aebischer, Patrick, Lutry, Switzerland
       Cytotherapeutics, Inc., Lincoln, RI, United States (U.S. corporation)
PA
                               20000222
PΙ
       US 6027721
       US 1996-650726
                               19960520 (8)
ΑI
DT
       Utility
FS
       Granted
LN.CNT 1429
INCL
       INCLM: 424/093.200
       INCLS: 424/452.000; 435/325.000; 435/465.000; 514/044.000
       NCLM: 424/093.200
NCL
       NCLS: 424/452.000; 435/325.000; 435/465.000; 514/044.000
       [7]
IC
       ICM: C12N015-85
       ICS: C12N015-00; A61K048-00; A61K009-48
       514/44; 424/93.1; 424/93.21; 424/93.2; 424/452; 435/325; 435/465
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 12 OF 25
                         MEDLINE
                                                         DUPLICATE 5
L4
     2000267823
                    MEDLINE
AN
DΝ
     20267823 PubMed ID: 10806392
     Leptin receptor-mediated regulation of cholinergic neurotransmitter
ΤI
     phenotype in cells of central nervous system origin.
ΑU
     Di Marco A; Demartis A; Gloaquen I; Lazzaro D; Delmastro P; Ciliberto G;
     Laufer R
     Istituto di Ricerche di Biologia Molecolare P. Angeletti (IRBM), Pomezia,
CS
     Italy.
SO
     EUROPEAN JOURNAL OF BIOCHEMISTRY, (2000 May) 267 (10) 2939-44.
     Journal code: 0107600. ISSN: 0014-2956.
CY
     GERMANY: Germany, Federal Republic of
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
FS
     Priority Journals
     200007
EM
ED
     Entered STN: 20000720
     Last Updated on STN: 20000720
     Entered Medline: 20000713
     ANSWER 13 OF 25
                         MEDLINE
                                                         DUPLICATE 6
L4
ΑN
     2001033559
                    MEDLINE
DN
     20527893 PubMed ID: 11078456
     Unlike leptin, ciliary neurotrophic factor does not reverse the
ΤI
     starvation-induced changes of serum corticosterone and hypothalamic
     neuropeptide levels but induces expression of hypothalamic inhibitors of
     leptin signaling.
     Ziotopoulou M; Erani D M; Hileman S M; Bjorbaek C; Mantzoros C S
ΑIJ
     Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard
CS
     Medical School, Boston, Massachusetts 02215, USA.
NC
     P30-DK-46200 (NIDDK)
SO
     DIABETES, (2000 Nov) 49 (11) 1890-6.
```

Journal code: 0372763. ISSN: 0012-1797.

```
СŸ
     United States
     Journal; Article; (JOURNAL
DT
LA
     English
     Abridged Index Medicus Journals; Priority Journals
FS
EM
     200011
     Entered STN: 20010322
ED
     Last Updated on STN: 20010322
     Entered Medline: 20001130
     ANSWER 14 OF 25 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
     2001:97474 BIOSIS
AN
DN
     PREV200100097474
     Ciliary neurotrophic factor reduces obesity in GTG-lesioned mice:
ΤI
     comparisons with leptin.
     Anderson, K. D. (1); Lambert, P. D.; Corcoran, T. L.; Murray, J. D.;
ΑU
     Thabet, K. E.; Yancopoulos, G. D.; Wiegand, S. J.
     (1) Regeneron Pharmaceuticals, Inc., Tarrytown, NY USA
CS
     Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
SO
     No.-440.13. print.
     Meeting Info.: 30th Annual Meeting of the Society of Neuroscience New
     Orleans, LA, USA November 04-09, 2000 Society for Neuroscience
     . ISSN: 0190-5295.
DT
     Conference
LA
     English
SL
     English
     ANSWER 15 OF 25 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
     2001:93932 BIOSIS
AN
     PREV200100093932
DN
     Ciliary neurotrophic factor reduces body weight by an entirely distinct
ΤI
     mechanism than the cachectic cytokine IL-1.
     Lambert, P. D. (1); Thabet, K. E.; Murray, J. D.; Corcoran, T. L.;
ΑU
     Yancopoulos, G. D.; Wiegand, S. J.
     (1) Regeneron Pharmaceuticals Inc, Tarrytown, NY USA
CS
     Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
SO
     No.-440.12. print.
     Meeting Info.: 30th Annual Meeting of the Society of Neuroscience New
     Orleans, LA, USA November 04-09, 2000 Society for Neuroscience
      . ISSN: 0190-5295.
DT
     Conference
     English
LA
     English
SL
     ANSWER 16 OF 25 USPATFULL
T.4
       1999:43744 USPATFULL
AN
       Ciliary neurotrophic factor receptor antibodies
ΤI
       Davis, Samuel, New York, NY, United States
TN
       Squinto, Stephen P., Irvington, NY, United States
       Furth, Mark E., Pelham, NY, United States
       Yancopoulos, George D., Briarcliff Manor, NY, United States
       Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.
PA
       corporation)
PΤ
       US 5892003
                               19990406
       US 1996-585258
                               19960111 (8)
ΑI
       Continuation of Ser. No. US 1993-1904, filed on 7 Jan 1993, now
RLI
       abandoned which is a continuation of Ser. No. US 1991-700677, filed on
       15 May 1991, now abandoned which is a continuation-in-part of Ser. No.
       US 1991-676647, filed on 28 Mar 1991, now patented, Pat. No. US 5426177
       which is a continuation-in-part of Ser. No. US 1990-532285, filed on 1
       Jun 1990, now abandoned
DT
       Utility
FS
       Granted
LN.CNT 2324
INCL
       INCLM: 530/388.220
NCL
       NCLM: 530/388.220
IC
       [6]
       ICM: C07K016-28
       530/388.22
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
DUPLICATE
     ANSWER 17 OF 25
                         MEDLINE
L4
                    MEDLINE
AN
     1999113842
               PubMed ID: 9916804
DN
     99113842
     Response of melanocortin-4 receptor-deficient mice to anorectic and
TI
     orexigenic peptides.
     Marsh D J; Hollopeter G; Huszar D; Laufer R; Yagaloff K A; Fisher S L;
ΑŪ
     Burn P; Palmiter R D
     Howard Hughes Medical Institute and Department of Biochemistry, University
CS
     of Washington, Seattle 98195, USA.
     NATURE GENETICS, (1999 Jan) 21 (1) 119-22.
SO
     Journal code: 9216904. ISSN: 1061-4036.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
FS
     Priority Journals
     199902
EΜ
     Entered STN: 19990223
ED
     Last Updated on STN: 20020510
     Entered Medline: 19990210
     ANSWER 18 OF 25 USPATFULL
L4
       1998:157495 USPATFULL
AN
       Nucleic acid molecule encoding ciliary neurotrophic factor receptor
TТ
       Davis, Samuel, New York, NY, United States
TN
       Squinto, Stephen P., Irvington, NY, United States
       Furth, Mark E., Pelham, NY, United States
       Yancopoulos, George D., Briarcliff Manor, NY, United States
       Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.
PA
       corporation)
                                19981215
PΙ
       US 5849897
                                19950519 (8)
       US 1995-445073
ΑI
       Division of Ser. No. US 1991-676647, filed on 28 Mar 1991, now patented,
RLT
       Pat. No. US 5426177 which is a continuation-in-part of Ser. No. US
       1990-532285, filed on 1 Jun 1990, now abandoned
DT
       Utility
FS
       Granted
LN.CNT 2105
       INCLM: 536/023.500
INCL
       INCLS: 435/069.100; 435/325.000; 435/252.300; 435/254.200; 435/348.000;
              435/320.100; 530/350.000
NCL
       NCLM:
              536/023.500
              435/069.100; 435/252.300; 435/254.200; 435/320.100; 435/325.000;
       NCLS:
              435/348.000; 530/350.000
IC
       [6]
       ICM: C12N015-12
       ICS: C07K014-705
       536/23.5; 536/24.31; 435/69.1; 435/240.2; 435/252.3; 435/254.11;
EXF
       435/325; 435/348; 435/320.1; 435/254.2; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 19 OF 25 USPATFULL
L4
       1998:68798 USPATFULL
AN
       Intracellular glutathione raising agents for therapeutic treatments
TT
       Noble, Mark David, London, England
IN
       Mayer, Margot, London, England
       Lugwig Institute for Cancer Research, New York, NY, United States (U.S.
PA
       corporation)
                                19980616
DТ
       US 5766873
       US 1994-189474
                                19940131 (8)
AΙ
DT
       Utility
       Granted
FS
LN.CNT 721
INCL
       INCLM: 435/025.000
       INCLS: 424/094.400
NCL
       NCLM: 435/025.000
       NCLS: 424/094.400
IC
       [6]
       ICM: C12Q001-26
```

```
424/85.1; 424/94.4; 530/3
EXF
                                    530/399; 435/25
CAS INDEXING IS AVAILABLE FOR THE
                                   PATENT.
1.4
     ANSWER 20 OF 25 USPATFULL
AN
       1998:64718 USPATFULL
       Antioxidants and intracellular gluthathione raising agents for
TI
       therapeutic treatments
IN
       Noble, Mark David, London, England
       Mayer, Margot, London, England
       Ludwig Institute for Cancer Research, New York, NY, United States (U.S.
PA
       corporation)
       US 5762922
PΙ
                                19980609
AΤ
       US 1994-270059
                               19940701 (8)
       Continuation-in-part of Ser. No. US 1994-189474, filed on 31 Jan 1994
RLI
DT
FS
       Granted
LN.CNT 1016
INCL
       INCLM: 424/085.400
       INCLS: 424/085.100; 530/351.000; 530/399.000
NCL
       NCLM: 424/085.400
       NCLS: 424/085.100; 530/351.000; 530/399.000
TC
       [6]
       ICM: A61K045-05
       ICS: A61K038-21
       424/85.1; 424/85.4; 530/351; 530/399
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 21 OF 25
                         MEDLINE
                                                         DUPLICATE 8
     1998290204
                    MEDLINE
AN
               PubMed ID: 9628240
DN
     98290204
     Screening for variability in the ciliary neurotrophic factor (CNTF
TT
     ) gene: no evidence for association with human obesity.
     Munzberg H; Tafel J; Busing B; Hinney A; Ziegler A; Mayer H; Siegfried W;
ΑU
     Matthaei S; Greten H; Hebebrand J; Hamann A
CS
     Medizinische Kernklinik und Poliklinik, Universitats-Krankenhaus
     Eppendorf, Hamburg, Germany.
     EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY AND DIABETES, (1998) 106 (2)
SO
     Journal code: 9505926. ISSN: 0947-7349.
     GERMANY: Germany, Federal Republic of
CY
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
     Priority Journals
FS
EM
     199809
     Entered STN: 19980917
ED
     Last Updated on STN: 20000303
     Entered Medline: 19980910
L4
     ANSWER 22 OF 25 USPATFULL
AN
       97:61667 USPATFULL
TI
       Methods of treatment using ciliary neurotrophic factor
       Davis, Samuel, New York, NY, United States
IN
       Squinto, Stephen P., Irvington, NY, United States
       Furth, Mark E., Pelham, NY, United States
       Yancopoulos, George D., Briarcliff Manor, NY, United States
PA
       Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.
       corporation)
ΡI
       US 5648334
                               19970715
AΙ
       US 1995-449329
                               19950524 (8)
RLI
       Division of Ser. No. US 1993-1904, filed on 7 Jan 1993, now abandoned
       which is a continuation of Ser. No. US 1991-700677, filed on 15 May
       1991, now abandoned which is a continuation-in-part of Ser. No. US
       1991-676647, filed on 28 Mar 1991, now patented, Pat. No. US 5426177
       which is a continuation-in-part of Ser. No. US 1990-532285, filed on 1
       Jun 1990, now abandoned
DT
       Utility
FS
       Granted
LN.CNT 2326
INCL
       INCLM: 514/012.000
```

```
INCLS: 514/002.000; 530/3 000; 530/399.000
NCL
       NCLM: 514/012.000
       NCLS: 514/002.000; 530/350.000; 530/399.000
TC
        [6]
        ICM: A61K038-17
        ICS: C07K014-475
EXF
       514/2; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
1.4
     ANSWER 23 OF 25
                          MEDLINE
                                                          DUPLICATE 9
AN
     97322394
                  MEDLINE
DN
     97322394
                PubMed ID: 9177239
     Ciliary neurotrophic factor corrects obesity and diabetes associated with
TТ
     leptin deficiency and resistance.
     Gloaguen I; Costa P; Demartis A; Lazzaro D; Di Marco A; Graziani R;
ΑIJ
     Paonessa G; Chen F; Rosenblum C I; Van der Ploeg L H; Cortese R; Ciliberto
     G; Laufer R
     Istituto di Ricerche di Biologia Molecolare P. Angeletti (IRBM), Via
CS
     Pontina km 30.600, 00040 Pomezia, Rome, Italy.
     PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
SO
     AMERICA, (1997 Jun 10) 94 (12) 6456-61.
     Journal code: 7505876. ISSN: 0027-8424.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
EM
     199707
ED
     Entered STN: 19970721
     Last Updated on STN: 20000303
     Entered Medline: 19970710
     ANSWER 24 OF 25 USPATFULL
T.4
AN
       95:54448 USPATFULL
TΙ
       Ciliary neurotrophic factor receptor
IN
       Davis, Samuel, New York, NY, United States
       Squinto, Stephen P., Irvington, NY, United States
       Furth, Mark E., Pelham, NY, United States
       Yancopoulos, George D., Briarcliff Manor, NY, United States
PA
       Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States (U.S.
       corporation)
PΤ
       US 5426177
                                19950620
AΤ
       US 1991-676647
                                19910328 (7)
RLT
       Continuation-in-part of Ser. No. US 1990-532285, filed on 1 Jun 1990,
       now abandoned
       Utility
DT
FS
       Granted
LN.CNT 2115
INCL
       INCLM: 530/395.000
       INCLS: 530/350.000; 530/839.000
NCL
       NCLM: 530/395.000
       NCLS:
              530/350.000; 530/839.000
IC
       [6]
       ICM: C07K013-00
EXF
       530/350; 530/387.1; 530/388.1; 530/388.22; 530/827; 530/839; 530/395;
       536/27; 435/6; 435/69.1; 435/172.3; 435/240.2; 435/7.1; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 25 OF 25
                         MEDLINE
                                                         DUPLICATE 10
AN
     92240402
                  MEDLINE
DN
     92240402
                PubMed ID: 1571789
    Reduced ciliary neuronotrophic factor-like activity in nerves from
     diabetic or galactose-fed rats.
     Calcutt N A; Muir D; Powell H C; Mizisin A P
    Department of Anesthesiology, University of California San Diego, La Jolla
     92093.
     14162 (NINDS)
    NS 16349-11
SO
    BRAIN RESEARCH, (1992 Mar 20) 575 (2) 320-4.
```

Journal code: 0045503. ISSN: 0006-8993.

CY Netherlands

Journal; Article; (JOURNAL ) English Priority Journals DT

LA

FS

ΕM 199205

ED Entered STN: 19920619

Last Updated on STN: 20000303 Entered Medline: 19920529